These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Amphotericin B nanohydrogel ocular formulation using alkyl glyceryl hyaluronic acid: Formulation, characterization, and in vitro evaluation. Banshoya K; Fujita C; Hokimoto Y; Ohnishi M; Inoue A; Tanaka T; Kaneo Y Int J Pharm; 2021 Dec; 610():121061. PubMed ID: 34481008 [TBL] [Abstract][Full Text] [Related]
10. Amphotericin B-loaded deformable lipid vesicles for topical treatment of cutaneous leishmaniasis skin lesions. Carvalheiro M; Vieira J; Faria-Silva C; Marto J; Simões S Drug Deliv Transl Res; 2021 Apr; 11(2):717-728. PubMed ID: 33534106 [TBL] [Abstract][Full Text] [Related]
11. Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles. Sousa-Batista AJ; Pacienza-Lima W; Ré MI; Rossi-Bergmann B Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():148-155. PubMed ID: 31331828 [TBL] [Abstract][Full Text] [Related]
12. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum. Gangneux JP; Sulahian A; Garin YJ; Derouin F Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278 [TBL] [Abstract][Full Text] [Related]
13. Development, characterization, and anti-leishmanial activity of topical amphotericin B nanoemulsions. Dos Santos Matos AP; Lopes DCDXP; Peixoto MLH; da Silva Cardoso V; Vermelho AB; Santos-Oliveira R; Viçosa AL; Holandino C; Ricci-Júnior E Drug Deliv Transl Res; 2020 Dec; 10(6):1552-1570. PubMed ID: 32676952 [TBL] [Abstract][Full Text] [Related]
14. Novel biodegradable poly(gamma-glutamic acid)-amphotericin B complexes show promise as improved amphotericin B formulations. Dinh T; Zia Q; Zubair S; Stapleton P; Singh R; Owais M; Somavarapu S Nanomedicine; 2017 Jul; 13(5):1773-1783. PubMed ID: 28216150 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterization, and mechanistic studies of a gold nanoparticle-amphotericin B covalent conjugate with enhanced antileishmanial efficacy and reduced cytotoxicity. Kumar P; Shivam P; Mandal S; Prasanna P; Kumar S; Prasad SR; Kumar A; Das P; Ali V; Singh SK; Mandal D Int J Nanomedicine; 2019; 14():6073-6101. PubMed ID: 31686803 [TBL] [Abstract][Full Text] [Related]
16. Biodistribution and Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182 [TBL] [Abstract][Full Text] [Related]
17. Targeted chemotherapy of visceral leishmaniasis by lactoferrin-appended amphotericin B-loaded nanoreservoir: in vitro and in vivo studies. Asthana S; Gupta PK; Jaiswal AK; Dube A; Chourasia MK Nanomedicine (Lond); 2015; 10(7):1093-109. PubMed ID: 25929567 [TBL] [Abstract][Full Text] [Related]
18. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469 [TBL] [Abstract][Full Text] [Related]
19. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation. Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313 [TBL] [Abstract][Full Text] [Related]
20. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice. Gershkovich P; Wasan EK; Sivak O; Li R; Zhu X; Werbovetz KA; Tidwell RR; Clement JG; Thornton SJ; Wasan KM J Antimicrob Chemother; 2010 Mar; 65(3):535-7. PubMed ID: 20026611 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]